Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00573989 · OUTCOME

Evaluation of Acute and Chronic Toxicity

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer · Source last updated 2019-01-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
events
Interval / dispersion
Not reported
Time frame
1 year

What was measured

Evaluate acute and chronic toxicity of the combined re-irradiation with radiosensitizing drugs: Pemetrexed and Erlotinib. Adverse events with Common Toxicity Criteria grades of 4 and 5 are reported for phase I and II.

Groups in this outcome

Erlotinib

Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Erlotinib25

Reported measurements

phase I
Values in events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Erlotinib18Not reportedNot reportedNot reportedNot reported
phase II
Values in events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Erlotinib6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        18
    title
    phase I
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    phase II
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Evaluate acute and chronic toxicity of the combined re-irradiation with radiosensitizing drugs: Pemetrexed and Erlotinib. Adverse events with Common Toxicity Criteria grades of 4 and 5 are reported for phase I and II.
groups
  1. description
    Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy
    id
    OG000
    title
    Erlotinib
param Type
NUMBER
reporting Status
POSTED
time Frame
1 year
title
Evaluation of Acute and Chronic Toxicity
type
SECONDARY
unit Of Measure
events

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice